CD4 and AIDS: Several factors may lead to higher cost-effectiveness ratios in the European setting, including higher rates of risk-factor-based, non-routine HIV testing, higher CD4 counts at diagnosis, and fewer patients presenting to care with AIDS-defining opportunistic diseases [42], [50].